John D. Sheppard, MD, MMSc, FACS, speaks about the future of pharmacological therapy for dry eye disease associated with meibomian gland dysfunction. This program was recorded prior to the approval of perfluorohexyloctane ophthalmic solution (formerly known as NOV03).

This activity is supported by an unrestricted educational grant from Bausch + Lomb.

Click here to view Dr. Sheppard's webinar event, which includes images from the talk.

Want to register with Evolve Medical Education? Click here.